A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

NCT ID: NCT06542874

Last Updated: 2025-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

448 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-07

Study Completion Date

2025-10-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes (T2D)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Sponsor staff involved in the clinical trial is masked according to company standard procedures.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NNC0487-0111 subcutaneous dose 4

NNC0487-0111 subcutaneous dose 4 treatment

Group Type EXPERIMENTAL

NNC0487-0111 subcutanous

Intervention Type DRUG

NNC0487-0111 administered subcutanously (under the skin)

NNC0487-0111 subcutaneous dose 5

NNC0487-0111 subcutaneous dose 5 treatment

Group Type EXPERIMENTAL

NNC0487-0111 subcutanous

Intervention Type DRUG

NNC0487-0111 administered subcutanously (under the skin)

NNC0487-0111 subcutaneous dose 6

NNC0487-0111 subcutaneous dose 6 treatment

Group Type EXPERIMENTAL

NNC0487-0111 subcutanous

Intervention Type DRUG

NNC0487-0111 administered subcutanously (under the skin)

Placebo oral

Placebo for oral treatment

Group Type PLACEBO_COMPARATOR

Placebo (NNC0487-0111 oral)

Intervention Type DRUG

NNC0487-0111 placebo administered orally (in the mouth)

NNC0487-0111 oral dose 1

NNC0487-0111 oral dose 1 treatment

Group Type EXPERIMENTAL

NNC0487-0111 oral

Intervention Type DRUG

NNC0487-0111 administered orally (in the mouth)

NNC0487-0111 oral dose 2

NNC0487-0111 oral dose 2 treatment

Group Type EXPERIMENTAL

NNC0487-0111 oral

Intervention Type DRUG

NNC0487-0111 administered orally (in the mouth)

NNC0487-0111 oral dose 3

NNC0487-0111 oral dose 3 treatment

Group Type EXPERIMENTAL

NNC0487-0111 oral

Intervention Type DRUG

NNC0487-0111 administered orally (in the mouth)

Placebo subcutaneous

Placebo for subcutaneous treatment

Group Type PLACEBO_COMPARATOR

Placebo (NNC0487-0111 subcutanous)

Intervention Type DRUG

NNC0487-0111 placebo administered subcutanously (under the skin)

NNC0487-0111 subcutaneous dose 1

NNC0487-0111 subcutaneous dose 1 treatment

Group Type EXPERIMENTAL

NNC0487-0111 subcutanous

Intervention Type DRUG

NNC0487-0111 administered subcutanously (under the skin)

NNC0487-0111 subcutaneous dose 2

NNC0487-0111 subcutaneous dose 2 treatment

Group Type EXPERIMENTAL

NNC0487-0111 subcutanous

Intervention Type DRUG

NNC0487-0111 administered subcutanously (under the skin)

NNC0487-0111 subcutaneous dose 3

NNC0487-0111 subcutaneous dose 3 treatment

Group Type EXPERIMENTAL

NNC0487-0111 subcutanous

Intervention Type DRUG

NNC0487-0111 administered subcutanously (under the skin)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NNC0487-0111 subcutanous

NNC0487-0111 administered subcutanously (under the skin)

Intervention Type DRUG

Placebo (NNC0487-0111 subcutanous)

NNC0487-0111 placebo administered subcutanously (under the skin)

Intervention Type DRUG

NNC0487-0111 oral

NNC0487-0111 administered orally (in the mouth)

Intervention Type DRUG

Placebo (NNC0487-0111 oral)

NNC0487-0111 placebo administered orally (in the mouth)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent.
* Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening.
* Stable daily dose(s) greater or equal to 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
* HbA1c of 7.0-10.0 procent (53-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.
* Body mass index between greater or equal to 23.0 and below 50.0 kg/m\^2.
* Able and willing to adhere to the protocol including wearing a continuous glucose monitoring (CGM) device provided for the study, as judged by the investigator.

* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novo Nordisk A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Transparency (dept. 2834)

Role: STUDY_DIRECTOR

Novo Nordisk A/S

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southern Cal Clinical Research

Santa Ana, California, United States

Site Status

Chase Medical Research LLC

Waterbury, Connecticut, United States

Site Status

Fleming Island Ctr for Clin Res

Fleming Island, Florida, United States

Site Status

Encore Medical Research LLC

Hollywood, Florida, United States

Site Status

South Broward Research LLC

Miramar, Florida, United States

Site Status

Florida Inst For Clin Res

Orlando, Florida, United States

Site Status

Cedar-Crosse Research Center

Chicago, Illinois, United States

Site Status

Advanced Internal Medicine, PLLC

Paducah, Kentucky, United States

Site Status

Medstar Research Institute_Hyattsville

Hyattsville, Maryland, United States

Site Status

MD Medical Research

Oxon Hill, Maryland, United States

Site Status

Arcturus HC PLC Troy Med Res

Troy, Michigan, United States

Site Status

Arcturus Healthcare, PLC

Troy, Michigan, United States

Site Status

Clinical Research Professionals

Chesterfield, Missouri, United States

Site Status

AMC Community Endocrinology

Albany, New York, United States

Site Status

Lucas Research Inc.

Morehead City, North Carolina, United States

Site Status

Piedmont Healthcare/Research

Statesville, North Carolina, United States

Site Status

Plains Clinical Research Center, LLC_Fargo

Fargo, North Dakota, United States

Site Status

Preferred Primary Care Physicians_Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

Health Concepts

Rapid City, South Dakota, United States

Site Status

Clinical Research Associates

Nashville, Tennessee, United States

Site Status

MidState Endocrine Associates

Nashville, Tennessee, United States

Site Status

Velocity Clinical Res-Dallas

Dallas, Texas, United States

Site Status

Victorium Clinical Research

Houston, Texas, United States

Site Status

Synergy Groups Medical

Houston, Texas, United States

Site Status

PlanIt Research, PLLC

Houston, Texas, United States

Site Status

Radiance Clinical Research

Lampasas, Texas, United States

Site Status

Tekton Research

McKinney, Texas, United States

Site Status

Hillcrest Family Health Center

Waco, Texas, United States

Site Status

Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.

Kyustendil, , Bulgaria

Site Status

IPSOMC Dr. Miglena Rizova Ltd.

Kyustendil, , Bulgaria

Site Status

UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases

Plovdiv, , Bulgaria

Site Status

UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic

Plovdiv, , Bulgaria

Site Status

DCC Sveti Georgi EOOD

Plovdiv, , Bulgaria

Site Status

Diagnostic-Consultative Centre "Sveti Georgi" Eood

Plovdiv, , Bulgaria

Site Status

Medical centre Regina Life Clinic EOOD

Sofia, , Bulgaria

Site Status

UMHAT "Aleksandrovska"

Sofia, , Bulgaria

Site Status

USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology

Sofia, , Bulgaria

Site Status

USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology

Sofia, , Bulgaria

Site Status

AIPSMC Dr. Artin Magardichyan EOOD

Varna, , Bulgaria

Site Status

Poliklinika Solmed

Zagreb, City of Zagreb, Croatia

Site Status

Clinical Hospital Centre Rijeka_Endocrinology

Rijeka, Primorje-Gorski Kotar County, Croatia

Site Status

KBC Rijeka, Endokrinologija

Rijeka, Primorje-Gorski Kotar County, Croatia

Site Status

Opca bolnica Karlovac

Karlovac, , Croatia

Site Status

Specijalna bolnica Krapinske Toplice - Endokrinologija

Krapinske Toplice, , Croatia

Site Status

Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology

Krapinske Toplice, , Croatia

Site Status

Klinicki bolnicki centar Osijek_Endocrinology

Osijek, , Croatia

Site Status

Klinicki bolnicki centar Osijek

Osijek, , Croatia

Site Status

Opca bolnica Varazdin_Endocrinology

Varaždin, , Croatia

Site Status

Opca bolnica Varazdin

Varaždin, , Croatia

Site Status

Zentrum fuer klinische Studien Suedbrandenburg GmbH

Elsterwerda, , Germany

Site Status

InnoDiab Forschung GmbH

Essen, , Germany

Site Status

Wendisch/Dahl Hamburg (DZHW)

Hamburg, , Germany

Site Status

Wendisch/Dahl Hamburg

Hamburg, , Germany

Site Status

Institut für Diabetesforschung GmbH Münster - Dr. med. Rose

Münster, , Germany

Site Status

RED-Institut für medizinische Forschung und Fortbildung GmbH

Oldenburg in Holstein, , Germany

Site Status

Iatriko Psychicou Private Clinic

Athens, , Greece

Site Status

U.G.H of Athens "Attikon"

Athens, , Greece

Site Status

"Laiko" General Hospital of Athens

Goudi/Athens, , Greece

Site Status

EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes

Thessaloniki, , Greece

Site Status

424 Military General Training Hospital - 2nd Department of Internal Medicine

Thessaloniki, , Greece

Site Status

424 Military General Training Hospital

Thessaloniki, , Greece

Site Status

"Thermi" Private Hosital

Thessaloniki, , Greece

Site Status

EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes

Thessaloniki, , Greece

Site Status

"Thermi" Private Hosital

Thessaloniki, , Greece

Site Status

Debreceni Egyetem

Debrecen, Hajdú-Bihar, Hungary

Site Status

Bajcsy-Zsilinszky Kórház

Budapest, , Hungary

Site Status

MH Egészségügyi Központ

Budapest, , Hungary

Site Status

Debreceni Egyetem

Debrecen, , Hungary

Site Status

Debreceni Egyetem

Debrecen, , Hungary

Site Status

Debreceni Egyetem

Debrecen, , Hungary

Site Status

Békés Megyei Központi Kórház

Gyula, , Hungary

Site Status

Somogy Vármegyei Kaposi Mór Oktató Kórház

Kaposvár, , Hungary

Site Status

Somogy Vármegyei Kaposi Mór Oktató Kórház

Kaposvár, , Hungary

Site Status

Heiwadai Hospital_Internal Medicine

Miyazaki, Miyazaki, Japan

Site Status

Heiwadai Hospital

Miyazaki, Miyazaki, Japan

Site Status

TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology

Aichi, , Japan

Site Status

Tokuyama clinic_Diabetic internal medicine

Chiba, , Japan

Site Status

Tokuyama clinic

Chiba, , Japan

Site Status

Akaicho Clinic

Chiba-shi, Chiba, , Japan

Site Status

Naka Kinen Clinic_Internal medicine

Ibaraki, , Japan

Site Status

Naka Kinen Clinic

Ibaraki, , Japan

Site Status

Tokyo-Eki Center-building Clinic_Internal Medicine

Tokyo, , Japan

Site Status

Tokyo-Eki Center-building Clinic

Tokyo, , Japan

Site Status

Fukuwa Clinic_Internal Medicine

Tokyo, , Japan

Site Status

Fukuwa Clinic

Tokyo, , Japan

Site Status

Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET

Krakow, Lesser Poland Voivodeship, Poland

Site Status

Formed 2 Sp. z o.o.

Oświęcim, Lesser Poland Voivodeship, Poland

Site Status

Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.

Legnica, Lower Silesian Voivodeship, Poland

Site Status

Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.

Legnica, Lower Silesian Voivodeship, Poland

Site Status

EKAMED sp. z o.o.

Lublin, Lublin Voivodeship, Poland

Site Status

ETG Siedlce

Siedlce, Masovian Voivodeship, Poland

Site Status

Specderm Poznanska Sp. j.

Bialystok, Podlaskie Voivodeship, Poland

Site Status

NZOZ Vita-Diabetica Malgorzata Buraczyk

Bialystok, Podlaskie Voivodeship, Poland

Site Status

Specderm Poznańska Spółka Jawna

Bialystok, , Poland

Site Status

EKAMED sp. z o.o.

Lublin, , Poland

Site Status

Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.

Ruda Śląska, , Poland

Site Status

PANSTWOWY INSTYTUT MEDYCZNY MSWiA

Warsaw, , Poland

Site Status

Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia

Lodz, Łódź Voivodeship, Poland

Site Status

SC Grand Med SRL

Oradea, Bihor County, Romania

Site Status

Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila

Bucharest, Bucurestii, Romania

Site Status

Spitalul Clinic Judetean Urgenta Cluj-Napoca

Cluj-Napoca, Cluj, Romania

Site Status

Sc Mediab Srl

Târgu Mureş, Mureș County, Romania

Site Status

Novus Medical Clinica SRL

Ploieşti, Prahova, Romania

Site Status

Mariodiab Clinic SRL

Brasov, , Romania

Site Status

Cabinet Medical Dr Geru SRL

Timișoara, , Romania

Site Status

Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara

Timișoara, , Romania

Site Status

Peter Farkas MD, s.r.o.

Šahy, Slovak Republic, Slovakia

Site Status

DENTAVIA s.r.o.

Poprad, , Slovakia

Site Status

DIABETOL, s.r.o.

Prešov, , Slovakia

Site Status

OLIVER - MED s.r.o.

Rimavská Sobota, , Slovakia

Site Status

MEDIVASA, s.r.o., Diabetologicka ambulancia

Žilina, , Slovakia

Site Status

Complejo Hospitalario Universitario A Coruña

A Coruña, , Spain

Site Status

Hospital Clinic i Provincial

Barcelona, , Spain

Site Status

Hospital Gregorio Marañón

Madrid, , Spain

Site Status

Hospital Universitario Marqués de Valdecilla

Santander, , Spain

Site Status

Clínica Nuevas Tecnologías en Diabetes y Endocrinología

Seville, , Spain

Site Status

Hospital Infanta Luisa

Seville, , Spain

Site Status

Hospital Nisa Sevilla Aljarafe

Seville, , Spain

Site Status

Hospital Vithas Sevilla

Seville, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria Croatia Germany Greece Hungary Japan Poland Romania Slovakia Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1296-9708

Identifier Type: OTHER

Identifier Source: secondary_id

2023-509412-28

Identifier Type: OTHER

Identifier Source: secondary_id

NN9490-7678

Identifier Type: -

Identifier Source: org_study_id